Views & Analysis
circassia

Circassia a cautionary tale for UK biotech, says Grainger

The UK biotech company is putting its huge failure in allergy treatment behind it.  But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D